LINCOLNSHIRE, Ill., December 01, 2025--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announces the launch of Tacrolimus Injection, USP 5 mg/mL. This launch signifies the first and only Tacrolimus ...
LINCOLNSHIRE, Ill., February 13, 2025--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announces the U.S Food and Drug Administration (FDA) approval of Tacrolimus Injection 5 mg/mL. Nexus’ Tacrolimus ...
SEATTLE, June 17, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global tacrolimus market is estimated to be valued at US$ 6,485.3 million in 2022 and is expected to exhibit a CAGR of ...
Nexus Pharmaceuticals, LLC announces the launch of Tacrolimus Injection, USP 5 mg/mL. This launch signifies the first and only Tacrolimus vial-format solution for healthcare providers and transplant ...
SEATTLE, June 17, 2022 /PRNewswire/ -- According to Coherent Market Insights , the global tacrolimus market is estimated to be valued at US$ 6,485.3 million in 2022 and is expected to exhibit a CAGR ...
Tacrolimus Injection is a crucial immunosuppressant indicated for the prophylaxis of organ rejection in patients receiving liver or kidney transplants. “We are pleased to share the launch of Nexus’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback